Skip to main content
SpringerLink
Log in

Cutaneous Adverse Effects of Neurologic Medications

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Life-threatening and benign drug reactions occur frequently in the skin, affecting 8 % of the general population and 2–3 % of all hospitalized patients, emphasizing the need for physicians to effectively recognize and manage patients with drug-induced eruptions. Neurologic medications represent a vast array of drug classes with cutaneous side effects. Approximately 7 % of the United States (US) adult population is affected by adult-onset neurological disorders, reflecting a large number of patients on neurologic drug therapies. This review elucidates the cutaneous reactions associated with medications approved by the US Food and Drug Administration (FDA) to treat the following neurologic pathologies: Alzheimer disease, amyotrophic lateral sclerosis, epilepsy, Huntington disease, migraine, multiple sclerosis, Parkinson disease, and pseudobulbar affect. A search of the literature was performed using the specific FDA-approved drug or drug classes in combination with the terms ‘dermatologic,’ ‘cutaneous,’ ‘skin,’ or ‘rash.’ Both PubMed and the Cochrane Database of Systematic Reviews were utilized, with side effects ranging from those cited in randomized controlled trials to case reports. It behooves neurologists, dermatologists, and primary care physicians to be aware of the recorded cutaneous adverse reactions and their severity for proper management and potential need to withdraw the offending medication.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  1. International drug monitoring: the role of national centres. Report of a WHO meeting. World Health Organ. Tech Rep Ser. 1972;498:1–25.

  2. Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem Immunol Allergy. 2012;97:1–17.

    Article  PubMed  Google Scholar 

  3. Ahmed AM, Pritchard S, Reichenberg J. A review of cutaneous drug eruptions. Clin Geriatr Med. 2013;29:527–45.

    Article  PubMed  Google Scholar 

  4. Turk BG, Gunaydin A, Ertam I, Ozturk G. Adverse cutaneous drug reactions among hospitalized patients: five year surveillance. Cutan Ocul Toxicol. 2013;32:41–5.

    Article  CAS  PubMed  Google Scholar 

  5. Svensson CK, Cowen EW, Gaspari AA. Cutaneous drug reactions. Pharmacol Rev. 2001;53:357–79.

    CAS  PubMed  Google Scholar 

  6. Bork K. Cutaneous adverse drug reactions. In: Burgdorf W, Plewig G, Wolff H, Landthaler M, editors. Braun-Falcos dermatol. 3rd ed. Heidelberg: Springer; 2009. p. 456–72.

    Chapter  Google Scholar 

  7. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the nomenclature review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832–6.

    Article  CAS  PubMed  Google Scholar 

  8. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stern RS, Anderson T, et al. Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995;333:1600–7.

    Article  CAS  PubMed  Google Scholar 

  9. Borlongan CV, Burns J, Tajiri N, Stahl CE, Weinbren NL, Shojo H, et al. Epidemiological survey-based formulae to approximate incidence and prevalence of neurological disorders in the United States: a meta-analysis. PloS One. 2013;8:e78490.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Hirtz D, Thurman DJ, Gwinn-Hardy K, Mohamed M, Chaudhuri AR, Zalutsky R. How common are the “common” neurologic disorders? Neurology. 2007;68:326–37.

    Article  CAS  PubMed  Google Scholar 

  11. Tarazona MJ, Mota AN, Gripp AC, Unterstell N, Bressan AL. Bullous pemphigoid and neurological disease: statistics from a dermatology service. An Bras Dermatol. 2015;90:280–2.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011;165:593–9.

    Article  CAS  PubMed  Google Scholar 

  13. Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case-control study. J Invest Dermatol. 2011;131:631–6.

    Article  CAS  PubMed  Google Scholar 

  14. Chosidow O, Doppler V, Bensimon G, Joly P, Salachas F, Lacomblez L, et al. Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease? Arch Dermatol. 2000;136:521–4.

    Article  CAS  PubMed  Google Scholar 

  15. Birks J, Harvey RJ. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev. 2006;(1):CD001190. doi:10.1002/14651858.CD001190.pub2.

  16. Bryant CA, Ouldred E, Jackson SHD, Kinirons MT. Purpuric rash with donepezil treatment. Br Med J. 1998;19:787.

    Article  Google Scholar 

  17. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dement Basel Switz. 1996;7:293–303.

  18. Jones RW. A review comparing the safety and tolerability of memantine with the acetylcholinesterase inhibitors. Int J Geriatr Psychiatry. 2010;25:547–53.

    CAS  PubMed  Google Scholar 

  19. Darreh-Shori T, Jelic V. Safety and tolerability of transdermal and oral rivastigmine in Alzheimer’s disease and Parkinson’s disease dementia. Expert Opin Drug Saf. 2010;9:167–76.

    Article  CAS  PubMed  Google Scholar 

  20. Golüke NMS, van Strien AM, Dautzenberg PJL, Jessurun N, Keijsers CJPW. Skin lesions after oral acetylcholinesterase inhibitor therapy: a case report. J Am Geriatr Soc. 2014;62:2012–3.

    Article  PubMed  Google Scholar 

  21. Makris M, Koulouris S, Koti I, Aggelides X, Kalogeromitros D. Maculopapular eruption to rivastigmine’s transdermal patch application and successful oral desensitization. Allergy. 2010;65:925–6.

    Article  CAS  PubMed  Google Scholar 

  22. Grieco T, Rossi M, Faina V, De Marco I, Pigatto P, Calvieri S. An atypical cutaneous reaction to rivastigmine transdermal patch. J Allergy. 2011;2011:1–2.

    Article  Google Scholar 

  23. Allain-Veyrac G, Lebreton A, Collonnier C, Jolliet P. First case of symmetric drug-related intertriginous and flexural exanthema (sdrife) due to rivastigmine? Am J Clin Dermatol. 2011;12:210–3.

    Article  PubMed  Google Scholar 

  24. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;(2):CD003154. doi:10.1002/14651858.CD003154.pub5.

  25. Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe alzheimer’s disease taking cholinesterase inhibitors. CNS Drugs. 2013;27:469–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev. 2012;(3):CD001447. doi:10.1002/14651858.CD001447.pub3.

  27. Sorenson EJ. An acute, life-threatening, hypersensitivity reaction to riluzole. Neurology. 2006;67:2260–1.

    Article  PubMed  Google Scholar 

  28. Błaszczyk B, Lasoń W, Czuczwar SJ. Antiepileptic drugs and adverse skin reactions: an update. Pharmacol Rep. 2015;67:426–34.

    Article  PubMed  CAS  Google Scholar 

  29. Arif H, Buchsbaum R, Weintraub D, Koyfman S, Salas-Humara C, Bazil CW, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology. 2007;68:1701–9.

    Article  CAS  PubMed  Google Scholar 

  30. Błaszczyk B, Szpringer M, Czuczwar SJ, Lasoń W. Single centre 20 year survey of antiepileptic drug-induced hypersensitivity reactions. Pharmacol Rep PR. 2013;65:399–409.

    Article  PubMed  Google Scholar 

  31. Alvestad S, Lydersen S, Brodtkorb E. Rash from antiepileptic drugs: influence by gender, age, and learning disability. Epilepsia. 2007;48:1360–5.

    Article  CAS  PubMed  Google Scholar 

  32. Perucca P, Gilliam FG. Adverse effects of antiepileptic drugs. Lancet Neurol. 2012;11:792–802.

    Article  CAS  PubMed  Google Scholar 

  33. Shear N, Knowles S, Sullivan J. Cutaneous reactions to drugs. In: Freedburg I, Eisen A, Wolff K, editors. Fitzpatrick’s dermatology in general medicine. 6th ed. New York: McGraw-Hill; 2003. p. 1330-7.

    Google Scholar 

  34. Yawalkar N. Drug-induced exanthems. Toxicology. 2005;209:131–4.

    Article  CAS  PubMed  Google Scholar 

  35. McKenna JK, Leiferman KM. Dermatologic drug reactions. Immunol Allergy Clin North Am. 2004;24:399–423 (vi).

  36. Chan HL, Stern RS, Arndt KA, Langlois J, Jick SS, Jick H, et al. The incidence of erythema multiforme, Stevens–Johnson syndrome, and toxic epidermal necrolysis. A population-based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol. 1990;126:43–7.

    Article  CAS  PubMed  Google Scholar 

  37. Mockenhaupt M. Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. J Dtsch Dermatol Ges J Ger Soc Dermatol JDDG. 2009;7:142–60 (quiz 161–2).

  38. Barvaliya M, Sanmukhani J, Patel T, Paliwal N, Shah H, Tripathi C. Drug-induced Stevens–Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study. J Postgrad Med. 2011;57:115–9.

    Article  CAS  PubMed  Google Scholar 

  39. Valeyrie-Allanore L, Sassolas B, Roujeau J-C. Drug-induced skin, nail and hair disorders. Drug Saf. 2007;30:1011–30.

    Article  CAS  PubMed  Google Scholar 

  40. Yang C-Y, Dao R-L, Lee T-J, Lu C-W, Yang C-H, Hung S-I, et al. Severe cutaneous adverse reactions to antiepileptic drugs in Asians. Neurology. 2011;77:2025–33.

    Article  CAS  PubMed  Google Scholar 

  41. Di Pascuale MA, Espana EM, Liu DT-S, Kawakita T, Li W, Gao YY, et al. Correlation of corneal complications with eyelid cicatricial pathologies in patients with Stevens–Johnson syndrome and toxic epidermal necrolysis syndrome. Ophthalmology. 2005;112:904–12.

    Article  PubMed  Google Scholar 

  42. Sharma VK, Sethuraman G. Adverse cutaneous reactions to drugs: an overview. J Postgrad Med. 1996;42:15–22.

    CAS  PubMed  Google Scholar 

  43. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part I. Clinical perspectives. J Am Acad Dermatol. 2013;68:693.e1–14 (quiz 706–8).

  44. Kardaun SH, Sekula P, Valeyrie-Allanore L, Liss Y, Chu CY, Creamer D, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169:1071–80.

    Article  CAS  PubMed  Google Scholar 

  45. Schlienger RG, Shear NH. Antiepileptic drug hypersensitivity syndrome. Epilepsia. 1998;39(Suppl 7):S3–7.

    Article  PubMed  Google Scholar 

  46. Wong IC, Mawer GE, Sander JW. Factors influencing the incidence of lamotrigine-related skin rash. Ann Pharmacother. 1999;33:1037–42.

    Article  CAS  PubMed  Google Scholar 

  47. Roquin G, Peres M, Lerolle N, Dib N, Mercat A, Croue A, et al. First report of lamotrigine-induced drug rash with eosinophilia and systemic symptoms syndrome with pancreatitis. Ann Pharmacother. 2010;44:1998–2000.

    Article  PubMed  Google Scholar 

  48. Hebert AA, Ralston JP. Cutaneous reactions to anticonvulsant medications. J Clin Psychiatry. 2001;62(Suppl 14):22–6.

    CAS  PubMed  Google Scholar 

  49. Arroyo S, Sander JW. Carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten. Neurology. 1999;53:1170–4.

    Article  CAS  PubMed  Google Scholar 

  50. Chopra S, Levell NJ, Cowley G, Gilkes JJ. Systemic corticosteroids in the phenytoin hypersensitivity syndrome. Br J Dermatol. 1996;134:1109–12.

    Article  CAS  PubMed  Google Scholar 

  51. Lafzi A, Farahani RMZ, Shoja MAM. Phenobarbital-induced gingival hyperplasia. J Contemp Dent Pract. 2007;8:50–6.

    PubMed  Google Scholar 

  52. Levy R, Mattson R, Meldrum B, Perucca E. Antiepileptic drugs. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2002.

    Google Scholar 

  53. Jones RT, Evans W, Mersfelder TL, Kavanaugh K. Rare red rashes: a case report of levetiracetam-induced cutaneous reaction and review of the literature. Am J Ther. 2014. doi:10.1097/MJT.0000000000000105.

    Google Scholar 

  54. Duong TA, Haddad C, Valeyrie-Allanore L, Sbidian E, Chosidow O, Wolkenstein P. Levetiracetam: a possible new inducer of toxic epidermal necrolysis and Stevens–Johnson syndrome in 2 cases. JAMA Dermatol. 2013;149:113–5.

    Article  PubMed  Google Scholar 

  55. Zou L-P, Ding C-H, Song Z-J, Li X-F. Stevens–Johnson syndrome induced by levetiracetam. Seizure. 2012;21:823–5.

    Article  PubMed  Google Scholar 

  56. Yesilova Y, Turan E, Sonmez A, Ozardali I. A case of erythema multiforme developing after levetiracetam therapy. Dermatol Online J. 2013;19:12.

    PubMed  Google Scholar 

  57. Beswick TC, Cohen JB. Dose-related levetiracetam-induced reticulated drug eruption. J Drugs Dermatol JDD. 2010;9:409–10.

    PubMed  Google Scholar 

  58. Gómez-Zorrilla S, Ferraz AV, Pedrós C, Lemus M, Peña C. Levetiracetam-induced drug reaction with eosinophilia and systemic symptoms syndrome. Ann Pharmacother. 2012;46:e20.

    Article  PubMed  Google Scholar 

  59. Cerminara C, Seri S, Bombardieri R, Pinci M, Curatolo P. Hypohidrosis during topiramate treatment: a rare and reversible side effect. Pediatr Neurol. 2006;34:392–4.

    Article  PubMed  Google Scholar 

  60. Guglani L, Sitwat B, Lower D, Kurland G, Weiner DJ. Elevated sweat chloride concentration in children without cystic fibrosis who are receiving topiramate therapy. Pediatr Pulmonol. 2012;47:429–33.

    Article  PubMed  Google Scholar 

  61. Castela E, Thomas P, Bronsard V, Lacour J-P, Ortonne J-P, Passeron T. Blue pseudochromhidrosis secondary to topiramate treatment. Acta Derm Venereol. 2009;89:538–9.

    Article  PubMed  Google Scholar 

  62. Aggarwal A, Kumar R, Sharma RC, Sharma DD. Topiramate induced pruritus in a patient with alcohol dependence. Indian J Dermatol. 2011;56:421–2.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Ochoa JG. Pruritus, a rare but troublesome adverse reaction of topiramate. Seizure. 2003;12:516–8.

    Article  PubMed  Google Scholar 

  64. Scheinfeld N, Spahn C. Palmar erythema due to topiramate. J Drugs Dermatol JDD. 2004;3:321–2.

    PubMed  Google Scholar 

  65. Chen Y-C, Chu C-Y, Hsiao C-H. Oxcarbazepine-induced Stevens–Johnson syndrome in a patient with HLA-B*1502 genotype. J Eur Acad Dermatol Venereol JEADV. 2009;23:702–3.

    Article  PubMed  Google Scholar 

  66. Cornell SL, DiBlasi D, Arora NS. drug reaction with eosinophilia and systemic symptoms: DRESS following initiation of oxcarbazepine with elevated human herpesvirus-6 titer. Case Rep Dermatol Med. 2014;2014:853281.

    PubMed  PubMed Central  Google Scholar 

  67. He N, Min F-L, Shi Y-W, Guo J, Liu X-R, Li B-M, et al. Cutaneous reactions induced by oxcarbazepine in Southern Han Chinese: incidence, features, risk factors and relation to HLA-B alleles. Seizure. 2012;21:614–8.

    Article  PubMed  Google Scholar 

  68. Massot A, Gimenez-Arnau A. Cutaneous adverse drug reaction type erythema multiforme major induced by eslicarbazepine. J Pharmacol Pharmacother. 2014;5:271–4.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Baulac M, Patten A, Giorgi L. Long-term safety and efficacy of zonisamide versus carbamazepine monotherapy for treatment of partial seizures in adults with newly diagnosed epilepsy: results of a phase III, randomized, double-blind study. Epilepsia. 2014;55:1534–43.

    Article  CAS  PubMed  Google Scholar 

  70. Okumura A, Ishihara N, Kato T, Hayakawa F, Kuno K, Watanabe K. Predictive value of acetylcholine stimulation testing for oligohidrosis caused by zonisamide. Pediatr Neurol. 2000;23:59–61.

    Article  CAS  PubMed  Google Scholar 

  71. Knudsen JF, Thambi LR, Kapcala LP, Racoosin JA. Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr Neurol. 2003;28:184–9.

    Article  PubMed  Google Scholar 

  72. Low PA, James S, Peschel T, Leong R, Rothstein A. Zonisamide and associated oligohidrosis and hyperthermia. Epilepsy Res. 2004;62:27–34.

    Article  CAS  PubMed  Google Scholar 

  73. Kaliyadan F, Manoj J, Venkitakrishnan S. Xerosis and pityriasis alba-like changes associated with zonisamide. Indian J Dermatol Venereol Leprol. 2008;74:165–6.

    Article  PubMed  Google Scholar 

  74. Shibuya R, Tanizaki H, Nakajima S, Koyanagi I, Kataoka TR, Miyachi Y, et al. DIHS/DRESS with remarkable eosinophilic pneumonia caused by zonisamide. Acta Derm Venereol. 2015;95:229–30.

    Article  PubMed  Google Scholar 

  75. Uhara H, Saiki M, Kawachi S, Ashida A, Oguchi S, Okuyama R. Clinical course of drug-induced hypersensitivity syndrome treated without systemic corticosteroids. J Eur Acad Dermatol Venereol JEADV. 2013;27:722–6.

    Article  CAS  PubMed  Google Scholar 

  76. Tohyama M, Hashimoto K, Yasukawa M, Kimura H, Horikawa T, Nakajima K, et al. Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome. Br J Dermatol. 2007;157:934–40.

    Article  CAS  PubMed  Google Scholar 

  77. Murata T, Endo Y, Katoh M, Miyachi Y, Kabashima K. Case of drug rash with eosinophilia and systemic symptoms induced by zonisamide and reactivation of human herpes virus 7. J Dermatol. 2011;38:918–20.

    CAS  PubMed  Google Scholar 

  78. Fujita Y, Hasegawa M, Nabeshima K, Tomita M, Murakami K, Nakai S, et al. Acute kidney injury caused by zonisamide-induced hypersensitivity syndrome. Intern Med Tokyo Jpn. 2010;49:409–13.

    Article  Google Scholar 

  79. Neuman MG, Shear NH, Malkiewicz IM, Kessas M, Lee AW, Cohen L. Predicting possible zonisamide hypersensitivity syndrome. Exp Dermatol. 2008;17:1045–51.

    Article  PubMed  Google Scholar 

  80. Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol. 2008;144:232–5.

    Article  CAS  PubMed  Google Scholar 

  81. Kaniwa N, Sugiyama E, Saito Y, Kurose K, Maekawa K, Hasegawa R, et al. Specific HLA types are associated with antiepileptic drug-induced Stevens–Johnson syndrome and toxic epidermal necrolysis in Japanese subjects. Pharmacogenomics. 2013;14:1821–31.

    Article  CAS  PubMed  Google Scholar 

  82. Biton V, Gil-Nagel A, Isojarvi J, Doty P, Hebert D, Fountain NB. Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials. Epilepsy Behav EB. 2015;52:119–27.

    Article  Google Scholar 

  83. Koubeissi MZ, Vismer M, Ehrlich A. Lacosamide-induced rash. Epileptic Disord Int Epilepsy J Videotape. 2014;16:380–3.

    Google Scholar 

  84. Yapici AK, Fidanci MK, Kilic S, Balamtekin N, Mutluay Arslan M, Yavuz ST, et al. Stevens–Johnson Syndrome triggered by a combination of clobazam, lamotrigine and valproic acid in a 7-year-old child. Ann Burns Fire Disasters. 2014;27:121–5.

    CAS  PubMed  PubMed Central  Google Scholar 

  85. Dang CD, Beets-Shay L, Kahn EC. Toxic epidermal necrolysis triggered by clobazam: a case report in a 13-year-old girl. Pediatr Dermatol. 2015;32:e102–3.

    Article  PubMed  Google Scholar 

  86. Redondo P, Vicente J, España A, Subira ML, De Felipe I, Quintanilla E. Photo-induced toxic epidermal necrolysis caused by clobazam. Br J Dermatol. 1996;135:999–1002.

    Article  CAS  PubMed  Google Scholar 

  87. Setterfield JF, Robinson R, MacDonald D, Calonje E. Coma-induced bullae and sweat gland necrosis following clobazam. Clinical dermatology. Concise report. Clin Exp Dermatol. 2000;25:215–8.

    Article  CAS  PubMed  Google Scholar 

  88. Amichai B, Grunwald MH. Erythema multiforme due to clonazepam—supportive evidence from the macrophage migration inhibition factor test. Clin Exp Dermatol. 1998;23:206–7.

    Article  CAS  PubMed  Google Scholar 

  89. Lee M-C, Su C-P, Wang C-H, Lan C-C, Wu T-W. Suspected clonazepam-induced bullous dermatosis in a patient with respiratory failure. J Clin Pharmacol. 2012;52:1607–9.

    Article  CAS  PubMed  Google Scholar 

  90. Gordon KB, Guitart J, Kuzel T, Salard D, Bakouche O, Domer P, et al. Pseudo-mycosis fungoides in a patient taking clonazepam and fluoxetine. J Am Acad Dermatol. 1996;34:304–6.

    Article  CAS  PubMed  Google Scholar 

  91. Munoli RN, Praharaj SK, Bhatt SM. Localized exfoliating rash with paresthesia possibly due to clonazepam. J Child Adolesc Psychopharmacol. 2012;22:320–1.

    Article  CAS  PubMed  Google Scholar 

  92. Schmidt D, Gram L, Brodie M, Krämer G, Perucca E, Kälviäinen R, et al. Tiagabine in the treatment of epilepsy—a clinical review with a guide for the prescribing physician. Epilepsy Res. 2000;41:245–51.

    Article  CAS  PubMed  Google Scholar 

  93. Bauer J, Cooper-Mahkorn D. Tiagabine: efficacy and safety in partial seizures—current status. Neuropsychiatr Dis Treat. 2008;4:731–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Adkins JC, Noble S. Tiagabine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs. 1998;55:437–60.

    Article  CAS  PubMed  Google Scholar 

  95. Iorio ML, Moretti U, Colcera S, Magro L, Meneghelli I, Motola D, et al. Use and safety profile of antiepileptic drugs in Italy. Eur J Clin Pharmacol. 2007;63:409–15.

    Article  CAS  PubMed  Google Scholar 

  96. Xiao Y, Gan L, Wang J, Luo M, Luo H. Vigabatrin versus carbamazepine monotherapy for epilepsy. Cochrane Database Syst Rev. 2015;11:CD008781.

  97. Kälviäinen R, Aikiä M, Saukkonen AM, Mervaala E, Riekkinen PJ. Vigabatrin vs carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study. Arch Neurol. 1995;52:989–96.

    Article  PubMed  Google Scholar 

  98. Chadwick D. Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study. Vigabatrin European Monotherapy Study Group. Lancet Lond Engl. 1999;354:13–9.

  99. Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826–36.

    Article  CAS  PubMed  Google Scholar 

  100. Smith TL, Baldwin A, Cunningham LL, Cook AM. Rash associated with pregabalin use. Ann Pharmacother. 2008;42:1899–902.

    Article  CAS  PubMed  Google Scholar 

  101. Bamanikar A, Dhobale S, Lokwani S. Pregabalin hypersensitivity in a patient treated for postherpetic neuralgia. Indian J Pharmacol. 2013;45:522–3.

    Article  PubMed  PubMed Central  Google Scholar 

  102. Wilton LV, Shakir S. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England. Epilepsia. 2002;43:983–92.

    Article  PubMed  Google Scholar 

  103. Lopez PR, Rachael T, Leicht S, Smalligan RD. Gabapentin-induced delusions of parasitosis. South Med J. 2010;103:711–2.

    Article  PubMed  Google Scholar 

  104. Gijsen VMGJ, de Wildt SN, Ito S. Probability of rash related to gabapentin therapy in a child. Ann Pharmacother. 2009;43:387–9.

    CAS  PubMed  Google Scholar 

  105. Ragucci MV, Cohen JM. Gabapentin-induced hypersensitivity syndrome. Clin Neuropharmacol. 2001;24:103–5.

    Article  CAS  PubMed  Google Scholar 

  106. Sahin S, Comert A, Akin O, Ayalp S, Karsidag S. Cutaneous drug eruptions by current antiepileptics: case reports and alternative treatment options. Clin Neuropharmacol. 2008;31:93–6.

    Article  PubMed  Google Scholar 

  107. Wollina U, Koch A, Krönert C, Köstler E. Gabapentin-induced generalized cutaneous small-vessel leukocytoclastic vasculitis. Int J Low Extrem Wounds. 2004;3:123–4.

    Article  PubMed  Google Scholar 

  108. Poon DYH, Law NM. A case of cutaneous leukocytoclastic vasculitis associated with gabapentin. Singap Med J. 2003;44:42–4.

    CAS  Google Scholar 

  109. DeToledo JC, Minagar A, Lowe MR, Ramsay RE. Skin eruption with gabapentin in a patient with repeated AED-induced Stevens–Johnson’s syndrome. Ther Drug Monit. 1999;21:137–8.

    Article  CAS  PubMed  Google Scholar 

  110. Schulze-Bonhage A, Hintz M. Perampanel in the management of partial-onset seizures: a review of safety, efficacy, and patient acceptability. Patient Prefer Adherence. 2015;9:1143–51.

    Article  PubMed  PubMed Central  Google Scholar 

  111. Shimabukuro K, Gibbon F, Kerstetter J, Tinsley C, Ashwal S. DRESS associated with perampanel administration in a child with drug-resistant epilepsy. Neurology. 2014;83:2188.

    Article  PubMed  PubMed Central  Google Scholar 

  112. Clark S, Antell A, Kaufman K. New antiepileptic medication linked to blue discoloration of the skin and eyes. Ther Adv Drug Saf. 2015;6:15–9.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  113. Garin Shkolnik T, Feuerman H, Didkovsky E, Kaplan I, Bergman R, Pavlovsky L, et al. Blue-gray mucocutaneous discoloration: a new adverse effect of ezogabine. JAMA Dermatol. 2014;150:984–9.

  114. Shahbaz S, Sivamani RK, Konia T, Burrall B. A case of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) related to rufinamide. Dermatol Online J. 2013;19:4.

    CAS  PubMed  Google Scholar 

  115. Chambel M, Mascarenhas MI, Regala J, Gouveia C, Prates S. Clinical Stevens–Johnson syndrome and rufinamide: a clinical case. Allergol Immunopathol (Madr). 2013;41:68–9.

  116. Ide M, Kato T, Nakata M, Saito K, Yoshida T, Awaya T, et al. A granulocytosis associated with rufinamide: a case report. Brain Dev. 2015;37:825–8.

    Article  PubMed  Google Scholar 

  117. Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with huntington’s and other diseases. Tremor Hyperkinetic Mov. 2013;3. doi:10.7916/D8BK1B2D.

  118. Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol. 2008;31:313–8.

    Article  CAS  PubMed  Google Scholar 

  119. Olesen J, Steiner TJ. The International classification of headache disorders, 2nd edn (ICDH-II). J Neurol Neurosurg Psychiatry. 2004;75:808–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  120. Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55:3–20.

    Article  PubMed  Google Scholar 

  121. Lipton RB, Diamond S, Reed M, Diamond ML, Stewart WF. Migraine diagnosis and treatment: results from the American Migraine Study II. Headache. 2001;41:638–45.

    Article  CAS  PubMed  Google Scholar 

  122. Siegel SJ, O’Neill C, Dubé LM, Kaldeway P, Morris R, Jackson D, et al. A unique iontophoretic patch for optimal transdermal delivery of sumatriptan. Pharm Res. 2007;24:1919–26.

    Article  CAS  PubMed  Google Scholar 

  123. Goldstein J, Smith TR, Pugach N, Griesser J, Sebree T, Pierce M. A sumatriptan iontophoretic transdermal system for the acute treatment of migraine. Headache. 2012;52:1402–10.

    Article  PubMed  Google Scholar 

  124. Merck Sharp & Dohme Corp. A randomized, placebo-controlled, parallel-groups, outpatient study to examine the safety, tolerability, and efficacy of single oral doses of MK0462 5 mg, MK0462 10 mg, and Sumatriptan 100 mg for acute treatment of migraine. In: ClinicalTrials.gov [Internet]. Bethesda: National Library of Medicine (US); Available from: https://clinicaltrials.gov/ct2/show/study/NCT00898677. Accessed 20 Aug 2015.

  125. Sanford M. Frovatriptan: a review of its use in the acute treatment of migraine. CNS Drugs. 2012;26:791–811.

    Article  CAS  PubMed  Google Scholar 

  126. Silberstein SD, Kori SH. Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine. CNS Drugs. 2013;27:385–94.

    Article  CAS  PubMed  Google Scholar 

  127. Drago F, Cogorno L, Agnoletti AF, Ciccarese G, Parodi A. A retrospective study of cutaneous drug reactions in an outpatient population. Pharm: Int. J. Clin; 2015.

    Google Scholar 

  128. Grando LR, Schmitt TAB, Bakos RM. Severe cutaneous reactions to drugs in the setting of a general hospital. An Bras Dermatol. 2014;89:758–62.

    Article  PubMed  PubMed Central  Google Scholar 

  129. Ward KE, Archambault R, Mersfelder TL. Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: a review of the literature. Am J Health Syst Pharm. 2010;67:206–13.

  130. Freitag FG, Shumate D. Current and investigational drugs for the prevention of migraine in adults and children. CNS Drugs. 2014;28:921–7.

    Article  CAS  PubMed  Google Scholar 

  131. Halevy S, Feuerman EJ. Psoriasiform eruption induced by propranolol. Cutis. 1979;24:95–8.

    CAS  PubMed  Google Scholar 

  132. Jensen HA, Mikkelsen HI, Wadskov S, Sondergaard J. Cutaneous reactions to propranolol (Inderal). Acta Med Scand. 1976;199:363–7.

    Article  CAS  PubMed  Google Scholar 

  133. Neumann HA, van Joost T. Adverse reactions of the skin to metoprolol and other beta-adrenoreceptor-blocking agents. Dermatologica. 1981;162:330–5.

    Article  CAS  PubMed  Google Scholar 

  134. Sondergaard J, Wadskov S, Jensen HA, Mikkelsen HI. Aggravation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol (Eraldin). Acta Derm Venereol. 1976;56:239–43.

    CAS  PubMed  Google Scholar 

  135. Heng MC, Heng MK. Beta-adrenoceptor antagonist-induced psoriasiform eruption. Clinical and pathogenetic aspects. Int J Dermatol. 1988;27:619–27.

    Article  CAS  PubMed  Google Scholar 

  136. Halevy S, Livni E. Psoriasis and psoriasiform eruptions associated with propranolol—the role of an immunological mechanism. Arch Dermatol Res. 1991;283:472–3.

    Article  CAS  PubMed  Google Scholar 

  137. Gold MH, Holy AK, Roenigk HH. Beta-blocking drugs and psoriasis. A review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol. 1988;19:837–41.

    Article  CAS  PubMed  Google Scholar 

  138. Stanford CW, Kollipara R, Melookaran AM, Hall JC. Palmoplantar pustular psoriasis following initiation of a beta-blocker: disease control with low-dose methotrexate. Cutis. 2014;94:153–5.

    PubMed  Google Scholar 

  139. Perry A, Sparling JD, Pennington M. Bullous pemphigoid following therapy with an oral beta-blocker. J Drugs Dermatol JDD. 2005;4:746–8.

    PubMed  Google Scholar 

  140. Stage AH, Humeniuk JM, Easley WK. Bullous pemphigoid of the vulva: a case report. Am J Obstet Gynecol. 1984;150:169–70.

    Article  CAS  PubMed  Google Scholar 

  141. Bajwa ZH, Sami N, Flory C. Severe acne as a side effect of propranolol and nadolol in a migraineur. Headache. 1999;39:758–60.

    Article  CAS  PubMed  Google Scholar 

  142. Szok D, Csáti A, Vécsei L, Tajti J. Treatment of chronic migraine with onabotulinumtoxinA: mode of action. Efficacy and safety. Toxins. 2015;7:2659–73.

    Article  PubMed  PubMed Central  Google Scholar 

  143. Brin MF, Boodhoo TI, Pogoda JM, James LM, Demos G, Terashima Y, et al. Safety and tolerability of onabotulinumtoxinA in the treatment of facial lines: a meta-analysis of individual patient data from global clinical registration studies in 1678 participants. J Am Acad Dermatol. 2009;61(961–70):e1–11.

    PubMed  Google Scholar 

  144. Mezaki T, Sakai R. Botulinum toxin and skin rash reaction. Mov Disord. 2005;20:770.

    Article  PubMed  Google Scholar 

  145. Roehm PC, Perry JD, Girkin CA, Miller NR. Prevalence of periocular depigmentation after repeated botulinum toxin A injections in African American patients. J Neuro Ophthalmol. 1999;19:7–9.

  146. Khan TT, Herne K, Dayan SH, Woodward JA. Facial blanching due to neurotoxins: proposed mechanisms. Dermatol Surg. 2013;39:24–9.

    Article  CAS  PubMed  Google Scholar 

  147. Gadient PM, Smith JH, Ryan SJ. Herpes zoster ophthalmicus following onabotulinumtoxinA administration for chronic migraine: a case report and literature review. Cephalalgia Int J Headache. 2015;35:443–8.

    Article  Google Scholar 

  148. Graber EM, Dover JS, Arndt KA. Two cases of herpes zoster appearing after botulinum toxin type a injections. J Clin Aesthetic Dermatol. 2011;4:49–51.

    Google Scholar 

  149. Frohman EM, Racke MK, Raine CS. Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med. 2006;354:942–55.

    Article  CAS  PubMed  Google Scholar 

  150. Compston A, Coles A. Multiple sclerosis. Lancet Lond Engl. 2008;372:1502–17.

    Article  CAS  Google Scholar 

  151. Brinkmann V, Billich A, Baumruker T, Heining P, Schmouder R, Francis G, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov. 2010;9:883–97.

    Article  CAS  PubMed  Google Scholar 

  152. Costello K, Halper J, Kalb R, Skutnik L, Rapp R. The use of disease-modifying therapies in multiple sclerosis: principles and current evidence. A consensus paper by the multiple sclerosis coalition. Mult Scler Coalit. 2015;1–37.

  153. Balak DMW, Hengstman GJD, Hajdarbegovic E, van den Brule RJP, Hupperts RMM, Thio HB. Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional study. BMC Neurol. 2013;13:146.

    Article  PubMed  PubMed Central  Google Scholar 

  154. Balak DMW, Hengstman GJD, Çakmak A, Thio HB. Cutaneous adverse events associated with disease-modifying treatment in multiple sclerosis: a systematic review. Mult Scler. 2012;18:1705–17.

    Article  PubMed  Google Scholar 

  155. Mancardi GL, Murialdo A, Drago F, Brusati C, Croce R, Inglese M, et al. Localized lipoatrophy after prolonged treatment with copolymer 1. J Neurol. 2000;247:220–1.

    Article  CAS  PubMed  Google Scholar 

  156. Edgar CM, Brunet DG, Fenton P, McBride EV, Green P. Lipoatrophy in patients with multiple sclerosis on glatiramer acetate. Can J Neurol Sci. 2004;31:58–63.

    Article  PubMed  Google Scholar 

  157. Ball NJ, Cowan BJ, Moore GRW, Hashimoto SA. Lobular panniculitis at the site of glatiramer acetate injections for the treatment of relapsing-remitting multiple sclerosis. A report of two cases. J Cutan Pathol. 2008;35:407–10.

    Article  PubMed  Google Scholar 

  158. Webster GF, Knobler RL, Lublin FD, Kramer EM, Hochman LR. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol. 1996;34:365–7.

    Article  CAS  PubMed  Google Scholar 

  159. Elgart GW, Sheremata W, Ahn YS. Cutaneous reactions to recombinant human interferon beta-1b: the clinical and histologic spectrum. J Am Acad Dermatol. 1997;37:553–8.

    Article  CAS  PubMed  Google Scholar 

  160. Ozden MG, Erel A, Erdem O, Oztas MO. Dermal fibrosis and cutaneous necrosis after recombinant interferon-beta1a injection in a multiple sclerosis patient. J Eur Acad Dermatol Venereol JEADV. 2005;19:112–3.

    Article  CAS  PubMed  Google Scholar 

  161. Casoni F, Merelli E, Bedin R, Martella A, Cesinaro A, Bertolotto A. Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNbeta 1b. Mult Scler. 2003;9:420–3.

    Article  PubMed  Google Scholar 

  162. Yang C-H, Chen CH, Chan H-L. Skin necrosis following a recombinant interferon-beta-1b injection. Chang Gung Med J. 2002;25:774–7.

    PubMed  Google Scholar 

  163. García-F-Villalta M, Daudén E, Sánchez J, Fraga J, Ramo C, García-Díez A. Local reactions associated with subcutaneous injections of both beta-interferon 1a and 1b. Acta Derm Venereol. 2001;81:152.

    Article  PubMed  Google Scholar 

  164. Albani C, Albani G. A case of cutaneous necrosis during interferon-beta 1b (B-IFN) therapy in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1997;62:418.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  165. Créange A, Lefaucheur JP. Focal neuropathy associated with cutaneous necrosis at the site of interferon-beta injection for multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68:395.

    Article  PubMed  PubMed Central  Google Scholar 

  166. Sheremata WA, Taylor JR, Elgart GW. Severe necrotizing cutaneous lesions complicating treatment with interferon beta-1b. N Engl J Med. 1995;332:1584.

    Article  CAS  PubMed  Google Scholar 

  167. Ohata U, Hara H, Yoshitake M, Terui T. Cutaneous reactions following subcutaneous beta-interferon-1b injection. J Dermatol. 2010;37:179–81.

    Article  PubMed  Google Scholar 

  168. Feldmann R, Löw-Weiser H, Duschet P, Gschnait F. Necrotizing cutaneous lesions caused by interferon beta injections in a patient with multiple sclerosis. Dermatol Basel Switz. 1997;195:52–3.

    Article  CAS  Google Scholar 

  169. Weinberg JM, Wolfe JT, Sood S, Saruk M, Rook AH, Spiers EM. Cutaneous necrosis associated with recombinant interferon injection. Report of three cases with interferon beta-1b and review of the literature. Acta Derm Venereol. 1997;77:146–8.

    CAS  PubMed  Google Scholar 

  170. Bosca I, Bosca M, Belenguer A, Evole M, Hernandez M, Casanova B, et al. Necrotising cutaneous lesions as a side effect of glatiramer acetate. J Neurol. 2006;253:1370–1.

    Article  PubMed  Google Scholar 

  171. Koontz D, Alshekhlee A. Embolia cutis medicamentosa following interferon beta injection. Mult Scler. 2007;13:1203–4.

    Article  CAS  PubMed  Google Scholar 

  172. Feldmann R, Schierl M, Rauschka H, Sator P-G, Breier F, Steiner A. Necrotizing skin lesions with involvement of muscle tissue after subcutaneous injection of glatiramer acetate. Eur J Dermatol EJD. 2009;19:385.

    PubMed  Google Scholar 

  173. Harde V, Schwarz T. Embolia cutis medicamentosa following subcutaneous injection of glatiramer acetate. J Dtsch Dermatol Ges. 2007;5:1122–3.

    Article  PubMed  Google Scholar 

  174. Gaudez C, Regnier S, Aractingi S, Heinzlef O. Livedo-like dermatitis (Nicolau’s syndrome) after injection of Copolymer-1 (Glatiramer acetate). Rev Neurol (Paris). 2003;159:571–3.

  175. Somani A-K, Swick AR, Cooper KD, McCormick TS. Severe dermatomyositis triggered by interferon beta-1a therapy and associated with enhanced type I interferon signaling. Arch Dermatol. 2008;144:1341–9.

    Article  CAS  PubMed  Google Scholar 

  176. Thouvenot E, Hillaire-Buys D, Bos-Thompson MA, Rigau V, Durand L, Guillot B, et al. Erythema nodosum and glatiramer acetate treatment in relapsing-remitting multiple sclerosis. Mult Scler. 2007;13:941–4.

    Article  CAS  PubMed  Google Scholar 

  177. Kumar N, Rodriguez M. Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler. 2004;10:85–6.

    Article  PubMed  Google Scholar 

  178. Gono T, Matsuda M, Shimojima Y, Kaneko K, Murata H, Ikeda S. Lupus erythematosus profundus (lupus panniculitis) induced by interferon-beta in a multiple sclerosis patient. J Clin Neurosci. 2007;14:997–1000.

    Article  PubMed  Google Scholar 

  179. Kocer B, Nazliel B, Oztas M, Batur HZ. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report. Eur J Neurol. 2009;16:e78–9.

    Article  CAS  PubMed  Google Scholar 

  180. Nolden S, Casper C, Kuhn A, Petereit HF. Jessner–Kanof lymphocytic infiltration of the skin associated with glatiramer acetate. Mult Scler. 2005;11:245–8.

    Article  CAS  PubMed  Google Scholar 

  181. Bayerl C, Bohland P, Jung EG. Systemic reaction to glatiramer acetate. Contact Dermatitis. 2000;43:62–3.

    CAS  PubMed  Google Scholar 

  182. Rauschka H, Farina C, Sator P, Gudek S, Breier F, Schmidbauer M. Severe anaphylactic reaction to glatiramer acetate with specific IgE. Neurology. 2005;64:1481–2.

    Article  CAS  PubMed  Google Scholar 

  183. Mazzeo L, Ricciardi L, Fazio MC, Fogliani O, Fedele R, Ferlazzo E, et al. Severe urticaria due to recombinant interferon beta-1a. Br J Dermatol. 2003;148:172.

    Article  CAS  PubMed  Google Scholar 

  184. Fusun Kalpaklioglu A, Baccioglu Kavut A, Erdemoglu AK. Desensitization in interferon-beta1a allergy: a case report. Int. Arch Allergy Immunol. 2009;149:178–80.

  185. Guijarro C, Benito-León J, Bermejo-Pareja F. Widespread urticaria due to intramuscular interferon beta-1a therapy for multiple sclerosis. Neurol Sci. 2011;32:309–11.

    Article  PubMed  Google Scholar 

  186. Brown DL, Login IS, Borish L, Powers PL. An urticarial IgE-mediated reaction to interferon beta-1b. Neurology. 2001;56:1416–7.

    Article  CAS  PubMed  Google Scholar 

  187. Cohen JA, Barkhof F, Comi G, Hartung H-P, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362:402–15.

    Article  CAS  PubMed  Google Scholar 

  188. Fruland JE, Sandermann S, Snow SN, Friedl A, Sharata HH. Skin necrosis with subsequent formation of squamous cell carcinoma after subcutaneous interferon beta injection. J Am Acad Dermatol. 1997;37:488–9.

    Article  CAS  PubMed  Google Scholar 

  189. Calabresi PA, Radue E-W, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:545–56.

    Article  CAS  PubMed  Google Scholar 

  190. Gasperini C, Ruggieri S, Mancinelli CR, Pozzilli C. Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. Ther Clin Risk Manag. 2013;9:73–85.

    CAS  PubMed  PubMed Central  Google Scholar 

  191. Kappos L, Radue E-W, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362:387–401.

    Article  CAS  PubMed  Google Scholar 

  192. Conzett KB, Kolm I, Jelcic I, Kamarachev J, Dummer R, Braun R, et al. Melanoma occurring during treatment with fingolimod for multiple sclerosis: a case report. Arch Dermatol. 2011;147:991.

    Article  PubMed  Google Scholar 

  193. Cohen JA, Khatri B, Barkhof F, Comi G, Hartung H-P, Montalban X, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry. 2015 (jnnp-2015-310597).

  194. Madray MM, Greene JF, Butler DF. Glatiramer acetate-associated, CD30+, primary, cutaneous, anaplastic large-cell lymphoma. Arch Neurol. 2008;65:1378–9.

    PubMed  Google Scholar 

  195. Tai YJ, Tam M. Fixed drug eruption with interferon-beta-1b. Australas J Dermatol. 2005;46:154–7.

    Article  PubMed  Google Scholar 

  196. Serarslan G, Okuyucu E, Melek I, Hakverdi S, Duman T. Widespread maculopapular rash due to intramuscular interferon beta-1a during the treatment of multiple sclerosis. Mult Scler. 2008;14:259–61.

    Article  CAS  PubMed  Google Scholar 

  197. Mehta CL, Tyler RJ, Cripps DJ. Granulomatous dermatitis with focal sarcoidal features associated with recombinant interferon beta-1b injections. J Am Acad Dermatol. 1998;39:1024–8.

    Article  CAS  PubMed  Google Scholar 

  198. Ziegler VR, Kränke B, Soyer P, Aberer W. Extensive cutaneous-subcutaneous infiltration as a side-effect of interferon-beta injection. Hautarzt Z Für Dermatol Venerol Verwandte Geb. 1998;49:310–2.

  199. Macbeth AE, Kendall BR, Smith A, Saldanha G, Harman KE. Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy. Br J Dermatol. 2007;157:624–5.

    Article  CAS  PubMed  Google Scholar 

  200. Pacheco MF, Jacobe H, Eagar TN, Stüve O. Reversible alopecia associated with glatiramer acetate. Arch Neurol. 2010;67:1154.

    Article  PubMed  Google Scholar 

  201. Bar-Or A, Pachner A, Menguy-Vacheron F, Kaplan J, Wiendl H. Teriflunomide and its mechanism of action in multiple sclerosis. Drugs. 2014;74:659–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  202. Miller AE, Wolinsky JS, Kappos L, Comi G, Freedman MS, Olsson TP, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13:977–86.

    Article  CAS  PubMed  Google Scholar 

  203. Gerschenfeld G, Servy A, Valeyrie-Allanore L, de Prost N, Cecchini J. Fatal toxic epidermal necrolysis in a patient on teriflunomide treatment for relapsing multiple sclerosis. Mult Scler. 2015;21(11):1476–7.

    Article  PubMed  Google Scholar 

  204. Xu Z, Zhang F, Sun F, Gu K, Dong S, He D. Dimethyl fumarate for multiple sclerosis. Cochrane Database Syst Rev. 2015;4:CD011076.

  205. Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69:759–77.

    Article  CAS  PubMed  Google Scholar 

  206. Jain N, Bhatti MT. Fingolimod-associated macular edema: incidence, detection, and management. Neurology. 2012;78:672–80.

    Article  CAS  PubMed  Google Scholar 

  207. Masera S, Chiavazza C, Mattioda A, Superti G, Beggiato E, Crosasso P, et al. Occurrence of ecchymotic angioedema-like cutaneous lesions as a possible side effect of fingolimod. Mult Scler. 2014;20:1666–7.

    Article  CAS  PubMed  Google Scholar 

  208. Samaraweera AP, Cohen SN, Akay EM, Evangelou N. Lymphomatoid papulosis: a cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis. Mult Scler. 2015;22(1):122–4.

    Article  PubMed  Google Scholar 

  209. Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci. 2015;16:16414–39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  210. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet Lond Engl. 2012;380:1819–28.

    Article  CAS  Google Scholar 

  211. Wray S, Arnold DL, Cohen J, Coles A, Fox E, Hartung H. Herpes infection risk reduced with acyclovir prophylaxis after alemtuzumab. In: Poster presented at the 2013 Annual Meeting of the Consortium for Multiple Sclerosis Centers, May 29-June 1, 2013, Orlando, FL. 2013.

  212. Havrdova E, Horakova D, Kovarova I. Alemtuzumab in the treatment of multiple sclerosis: key clinical trial results and considerations for use. Ther Adv Neurol Disord. 2015;8:31–45.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  213. Menge T, Stüve O, Kieseier BC, Hartung H-P. Alemtuzumab: the advantages and challenges of a novel therapy in MS. Neurology. 2014;83:87–97.

    Article  CAS  PubMed  Google Scholar 

  214. Planas R, Martin R, Sospedra M. Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. Patient Relat Outcome Meas. 2014;5:25–33.

    PubMed  PubMed Central  Google Scholar 

  215. O’Connor P, Goodman A, Kappos L, Lublin F, Polman C, Rudick RA, et al. Long-term safety and effectiveness of natalizumab redosing and treatment in the STRATA MS Study. Neurology. 2014;83:78–86.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  216. Gutwinski S, Erbe S, Münch C, Janke O, Müller U, Haas J. Severe cutaneous Candida infection during natalizumab therapy in multiple sclerosis. Neurology. 2010;74:521–3.

    Article  CAS  PubMed  Google Scholar 

  217. Krumbholz M, Pellkofer H, Gold R, Hoffmann LA, Hohlfeld R, Kümpfel T. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol. 2007;64:1331–3.

    Article  PubMed  Google Scholar 

  218. Cornblath DR, Bienen EJ, Blight AR. The safety profile of dalfampridine extended release in multiple sclerosis clinical trials. Clin Ther. 2012;34:1056–69.

    Article  CAS  PubMed  Google Scholar 

  219. Turnbull K, Caslake R, Macleod AD, Ives N, Stowe R, Counsell C. Monoamine oxidase B inhibitors for early Parkinson's disease. Cochrane Database Syst Rev. 2005;(3):CD004898. doi:10.1002/14651858.CD004898.pub2.

  220. Montastruc JL, Chaumerliac C, Desboeuf K, Manika M, Bagheri H, Rascol O, et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. Clin Neuropharmacol. 2000;23:271–5.

    Article  CAS  PubMed  Google Scholar 

  221. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002;59:1937–43.

    Article  Google Scholar 

  222. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol. 2005;62:241–8.

    Article  Google Scholar 

  223. Teva Pharmaceutical Industries Ltd. Azilect(R) package insert. Kfar Saba, Israel: Teva Pharmaceutical Industries Ltd; 2006.

  224. Boehringer Ingelheim International GmbH. Mirapex(R) package insert. Ridgefield: Boehringer Ingelheim International GmbH; 2006.

    Google Scholar 

  225. GlaxoSmithKline. Requip(R) package insert. Research Triangle Park: GlaxoSmithKline; 2005.

  226. Valeant Pharmaceuticals International. Zelapar(R) package insert. Costa Mesa: Valeant Pharmaceuticals International; 2006.

    Google Scholar 

  227. Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, et al. Skin cancer and Parkinson’s disease. Mov Disord. 2010;25:139–48.

    Article  PubMed  Google Scholar 

  228. Vermeij J-D, Winogrodzka A, Trip J, Weber WEJ. Parkinson’s disease, levodopa-use and the risk of melanoma. Parkinsonism Relat. Disord. 2009;15:551–3.

    Article  PubMed  Google Scholar 

  229. Fleischer AB, Resnick SD. Livedo reticularis. Dermatol Clin. 1990;8:347–54.

    PubMed  Google Scholar 

  230. Gibbs MB, English JC, Zirwas MJ. Livedo reticularis: an update. J Am Acad Dermatol. 2005;52:1009–19.

    Article  PubMed  Google Scholar 

  231. Strowd LC, Lee AD, Yosipovitch G. Livedo reticularis associated with rasagiline (azilect). J Drugs Dermatol JDD. 2012;11:764–5.

    PubMed  Google Scholar 

  232. Quaresma MV, Gomes ACD, Serruya A, Vendramini DL, Braga L, Buçard AM. Amantadine-induced livedo reticularis—case report. An Bras Dermatol. 2015;90:745–7.

    Article  PubMed  PubMed Central  Google Scholar 

  233. Singer C, Papapetropoulos S, Gonzalez MA, Roberts EL, Lieberman A. Rimantadine in Parkinson’s disease patients experiencing peripheral adverse effects from amantadine: report of a case series. Mov Disord. 2005;20:873–7.

    Article  PubMed  Google Scholar 

  234. Vollum DI, Parkes JD, Doyle D. Livedo reticularis during amantadine treatment. Br Med J. 1971;2:627–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  235. Sladden MJ, Nicolaou N, Johnston GA, Hutchinson PE. Livedo reticularis induced by amantadine. Br J Dermatol. 2003;149:656–8.

    Article  CAS  PubMed  Google Scholar 

  236. Rana AQ, Masroor MS. Patient perception of Levido reticularis due to amantadine. Int J Neurosci. 2012;122:363–6.

    Article  CAS  PubMed  Google Scholar 

  237. Eggert K, Oertel WH, Lees AJ. German competence network on Parkinson’s disease. Safety and efficacy of tolcapone in the long-term use in Parkinson disease: an observational study. Clin Neuropharmacol. 2014;37:1–5.

    Article  CAS  PubMed  Google Scholar 

  238. Olanow CW, Watkins PB. Tolcapone: an efficacy and safety review (2007). Clin Neuropharmacol. 2007;30:287–94.

    Article  CAS  PubMed  Google Scholar 

  239. Olanow CW, Kieburtz K, Stern M, Watts R, Langston JW, Guarnieri M, et al. Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. Arch Neurol. 2004;61:1563.

    Article  CAS  PubMed  Google Scholar 

  240. Foti C, Cassano N, De Mari M, Sorino M, Vena GA. Bullous skin eruption associated with entacapone. Int J Dermatol. 2004;43:471–2.

    Article  PubMed  Google Scholar 

  241. Marsala SZ, Gioulis M, Ceravolo R, Tinazzi M. A systematic review of catechol-O-methyltransferase inhibitors: efficacy and safety in clinical practice. Clin Neuropharmacol. 2012;35:185–90.

    Article  CAS  PubMed  Google Scholar 

  242. Kuoppamäki M, Vahteristo M, Ellmén J, Kieburtz K. Pooled analysis of phase III with entacapone in Parkinson’s disease. Acta Neurol Scand. 2014;130:239–47.

    Article  PubMed  CAS  Google Scholar 

  243. Elahmed HH. Phototoxic rash during therapy with pramipexole in a patient with restless Legs syndrome. Sultan Qaboos Univ Med J. 2013;13:190–1.

    Article  PubMed  PubMed Central  Google Scholar 

  244. Tan EK, Ondo W. Clinical characteristics of pramipexole-induced peripheral edema. Arch Neurol. 2000;57:729–32.

    Article  CAS  PubMed  Google Scholar 

  245. Makumi CW, Asgharian A, Ellis J, Shaikh S, Jimenez T, VanMeter S. Long-term, open-label, safety study of once-daily ropinirole extended/prolonged release in early and advanced Parkinson’s disease. Int J Neurosci. 2016;126(1):30–8.

    Article  PubMed  Google Scholar 

  246. Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, et al. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508.

    Article  CAS  PubMed  Google Scholar 

  247. Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, et al. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol. 2004;61:1044–53.

    PubMed  Google Scholar 

  248. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. N Engl J Med. 2000;342:1484–91.

    Article  CAS  PubMed  Google Scholar 

  249. Goetz CG. Skin rash associated with Sinemet 25/100. N Engl J Med. 1983;309:1387–8.

    CAS  PubMed  Google Scholar 

  250. Chou KL, Stacy MA. Skin rash associated with Sinemet does not equal levodopa allergy. Neurology. 2007;68:1078–9.

    Article  CAS  PubMed  Google Scholar 

  251. Liu R, Gao X, Lu Y, Chen H. Meta-analysis of the relationship between Parkinson disease and melanoma. Neurology. 2011;76:2002–9.

    Article  PubMed  PubMed Central  Google Scholar 

  252. Pioro EP. Review of dextromethorphan 20 mg/quinidine 10 mg (NUEDEXTA®) for Pseudobulbar affect. Neurol Ther. 2014;3:15–28.

    Article  PubMed  PubMed Central  Google Scholar 

  253. Schoedel KA, Morrow SA, Sellers EM. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatr Dis Treat. 2014;10:1161–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  254. Cohen IS, Jick H, Cohen SI. Adverse reactions to quinidine in hospitalized patients: findings based on data from the Boston Collaborative Drug Surveillance Program. Prog Cardiovasc Dis. 1977;20:151–63.

    Article  CAS  PubMed  Google Scholar 

  255. Conroy EA, Liranzo MO, McMahon J, Steck WD, Tuthill RJ. Quinidine-induced pigmentation. Cutis. 1996;57:425–7.

    CAS  PubMed  Google Scholar 

  256. Mahler R, Sissons W, Watters K. Pigmentation induced by quinidine therapy. Arch Dermatol. 1986;122:1062–4.

    Article  CAS  PubMed  Google Scholar 

  257. Birek C, Main JH. Two cases of oral pigmentation associated with quinidine therapy. Oral Surg Oral Med Oral Pathol. 1988;66:59–61.

    Article  CAS  PubMed  Google Scholar 

  258. Chang C, Gershwin ME. Drug-induced lupus erythematosus: incidence, management and prevention. Drug Saf. 2011;34:357–74.

    Article  CAS  PubMed  Google Scholar 

  259. Shalit M, Flugelman MY, Harats N, Galun E, Ackerman Z, Kopolovic J, et al. Quinidine-induced vasculitis. Arch Intern Med. 1985;145:2051–2.

    Article  CAS  PubMed  Google Scholar 

  260. Holt RJ. Uncharacteristic cutaneous reactions induced by quinidine. Drug Intell Clin Pharm. 1982;16:615–6.

    CAS  PubMed  Google Scholar 

  261. Adornato MC. Toxic epidermal necrolysis associated with quinidine administration. N Y State Dent J. 2000;66:38–40.

    CAS  PubMed  Google Scholar 

  262. Otero Rivas MM, Sánchez Sambucety P, García-Ruiz de Morales JM, Pérez Paredes G, Rodríguez Prieto MA. Acute generalized exanthematous pustulosis due to dextromethorphan. Dermatol Online J. 2013;19:20030.

  263. Pattee GL, Wymer JP, Lomen-Hoerth C, Appel SH, Formella AE, Pope LE. An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions. Curr Med Res Opin. 2014;30:2255–65.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  264. Dodiuk-Gad RP, Chung W-H, Valeyrie-Allanore L, Shear NH. Stevens–Johnson syndrome and toxic epidermal necrolysis: an update. Am J Clin Dermatol. 2015;16(6):475–93.

    Article  PubMed  Google Scholar 

  265. Bruno TF, Grewal P. Erythroderma: a dermatologic emergency. CJEM. 2009;11:244–6.

    PubMed  Google Scholar 

  266. Husain Z, Reddy BY, Schwartz RA. DRESS syndrome: part II. Management and therapeutics. J Am Acad Dermatol. 2013;68:709.e1–9 (quiz 718–20).

  267. Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): a review and update. J Am Acad Dermatol. 2015;73:843–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Baylor College of Medicine, Houston, TX, USA

    Eman Bahrani & Chloe E. Nunneley

  2. Department of Dermatology, Baylor College of Medicine, Houston, TX, USA

    Sylvia Hsu

  3. Department of Neurology, Baylor College of Medicine, 7200 Cambridge St., 9th Floor, Houston, TX, 77030, USA

    Joseph S. Kass

Authors
  1. Eman Bahrani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chloe E. Nunneley
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sylvia Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Joseph S. Kass
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph S. Kass.

Ethics declarations

Funding

No sources of funding were used in the preparation of this manuscript.

Conflicts of interest

Eman Bahrani, Chloe E. Nunneley, Sylvia Hsu, and Joseph S. Kass have no financial or other relationships that might lead to a conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bahrani, E., Nunneley, C.E., Hsu, S. et al. Cutaneous Adverse Effects of Neurologic Medications. CNS Drugs 30, 245–267 (2016). https://doi.org/10.1007/s40263-016-0318-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-016-0318-7

Keywords

Search

Navigation